Anbio Biotechnology Class A Ordinary Shares(NNNN)Earnings, Financials & Key Ratios
NNNN•NASDAQ
297.1× P/E·Price updated Jun 19, 2026
AboutAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.Show more
- Revenue$8M+21.9%
- EBITDA$3M+30.0%
- Net Income$2M+5.3%
- EPS (Diluted)0.06+366.7%
- Gross Margin71.9%+43.6%
- EBITDA Margin31.36%+6.6%
- Operating Margin24.38%-16.6%
- Net Margin28.99%-13.7%
- ROE14.83%-10.0%
NNNN Key Insights
Anbio Biotechnology Class A Ordinary Shares (NNNN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 54.7%
- ✓FCF machine: 25.4% free cash flow margin
- ✓Share count reduced 77.5% through buybacks
- ✓Healthy 5Y average net margin of 40.6%
✗Weaknesses
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 40.9x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NNNN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NNNN Price & Volume
Anbio Biotechnology Class A Ordinary Shares (NNNN) stock price & volume — 10-year historical chart
Loading chart...
NNNN Growth Metrics
Anbio Biotechnology Class A Ordinary Shares (NNNN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years22.72%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-2.19%
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years30.15%
TTM-
Return on Capital
10 Years64.71%
5 Years64.71%
3 Years54%
Last Year12.47%
NNNN Recent Earnings
Anbio Biotechnology Class A Ordinary Shares (NNNN) EPS & revenue vs analyst estimates — last 1 quarters
Q2 2026Latest
Apr 7, 2026Metric
Actual
Est
EPS
$0.07
—
Rev
$5M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 7, 2026 | $0.07 | $5M |
Based on last 1 quarters of dataView full earnings history →
NNNN Peer Comparison
Anbio Biotechnology Class A Ordinary Shares (NNNN) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CLOV | 2.59B | 5.00 | -29.41 | 40.34% | -2.58% | -17.08% | ||
 ACHC | 2.29B | 24.87 | -2.05 | 5.04% | -32.84% | -40.92% | 1.24 | |
 QDEL | 930.68M | 13.67 | -0.82 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CHEK | 10.88M | 1.86 | -0.43 | -226.19% | ||||
 IDXX | 44.64B | 562.09 | 42.97 | 10.42% | 24.63% | 70.87% | 0.67 | |
 BIO | 7.63B | 282.44 | 10.13 | 0.65% | 6.52% | 2.4% | 0.21 | |
 NEOG | 2.03B | 9.31 | -1.85 | -3.2% | -68.47% | -28.64% | 0.44 | |
 ALGN | 13.04B | 182.08 | 32.23 | 0.9% | 10.5% | 10.7% | 0.03 |
Compare NNNN vs Peers
Anbio Biotechnology Class A Ordinary Shares (NNNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NNNN Income Statement
Anbio Biotechnology Class A Ordinary Shares (NNNN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
Sales/Revenue | 4.43M | 23.54M | 6.71M | 8.19M |
Revenue Growth % | - | 431.67% | -71.49% | 21.95% |
Cost of Goods Sold | 1.89M | 10.98M | 3.35M | 2.3M |
COGS % of Revenue | 42.6% | 46.64% | 49.93% | 28.1% |
Gross Profit | 2.54M▲ 0% | 12.56M▲ 394.3% | 3.36M▼ 73.2% | 5.89M▲ 75.1% |
Gross Margin % | 57.4% | 53.36% | 50.07% | 71.9% |
Gross Profit Growth % | - | 394.25% | -73.25% | 75.11% |
Operating Expenses | 86.09K | 2.37M | 1.4M | 3.89M |
OpEx % of Revenue | 1.94% | 10.06% | 20.86% | 47.53% |
Selling, General & Admin | 86.09K | 2.17M | 1.27M | 3.44M |
SG&A % of Revenue | 1.94% | 9.21% | 18.85% | 41.98% |
Research & Development | 0 | 200K | 134.7K | 454.23K |
R&D % of Revenue | - | 0.85% | 2.01% | 5.55% |
Other Operating Expenses | 0 | 0 | 0 | 0 |
Operating Income | 2.46M▲ 0% | 10.2M▲ 315.2% | 1.96M▼ 80.8% | 2M▲ 1.8% |
Operating Margin % | 55.46% | 43.3% | 29.22% | 24.38% |
Operating Income Growth % | - | 315.15% | -80.77% | 1.76% |
EBITDA | 2.54M | 10.2M | 1.97M | 2.57M |
EBITDA Margin % | 57.26% | 43.33% | 29.41% | 31.36% |
EBITDA Growth % | - | 302.31% | -80.65% | 30.03% |
D&A (Non-Cash Add-back) | 0 | 6.25K | 13.04K | 0 |
EBIT | 2.54M | 10.02M | 2.25M | 2.37M |
Net Interest Income | 0 | 34.25K | 165.34K | 337.51K |
Interest Income | 0 | 42.24K | 165.34K | 337.51K |
Interest Expense | 0 | 8K | 0 | 0 |
Other Income/Expense | 79.94K | -184.41K | 292.78K | 377.48K |
Pretax Income | 2.54M▲ 0% | 10.01M▲ 294.8% | 2.25M▼ 77.5% | 2.37M▲ 5.3% |
Pretax Margin % | 57.26% | 42.52% | 33.58% | 28.99% |
Income Tax | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% |
Net Income | 2.54M▲ 0% | 10.01M▲ 294.8% | 2.25M▼ 77.5% | 2.37M▲ 5.3% |
Net Margin % | 57.26% | 42.52% | 33.58% | 28.99% |
Net Income Growth % | - | 294.79% | -77.49% | 5.29% |
Net Income (Continuing) | 2.54M | 10.01M | 2.25M | 2.37M |
Discontinued Operations | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.03▲ 0% | 0.07▲ 174.0% | 0.01▼ 82.8% | 0.06▲ 366.7% |
EPS Growth % | - | 174.02% | -82.76% | 366.67% |
EPS (Basic) | 0.03 | 0.07 | 0.02 | 0.06 |
Diluted Shares Outstanding | 100M | 143.89M | 187.78M | 42.29M |
Basic Shares Outstanding | 100M | 143.89M | 143.89M | 42.29M |
Dividend Payout Ratio | - | - | - | - |
NNNN Balance Sheet
Anbio Biotechnology Class A Ordinary Shares (NNNN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
Total Current Assets | 4.92M | 13.94M | 15.75M | 18.53M |
Cash & Short-Term Investments | 4.18M | 8.67M | 9.69M | 11.76M |
Cash Only | 4.18M | 7.1M | 9.69M | 11.76M |
Short-Term Investments | 0 | 1.57M | 0 | 0 |
Accounts Receivable | 717.5K | 3.58K | 1.88M | 1.06M |
Days Sales Outstanding | 59.14 | 0.06 | 102.5 | 47.48 |
Inventory | 0 | 353.87K | 0 | 0 |
Days Inventory Outstanding | - | 11.76 | - | - |
Other Current Assets | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 0 | 15.05K | 62.14K | 387.44K |
Property, Plant & Equipment | 0 | 12.06K | 0 | 0 |
Fixed Asset Turnover | - | 1952.45x | - | - |
Goodwill | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 2.99K | 62.14K | 387.44K |
Total Assets | 4.92M▲ 0% | 13.96M▲ 184.0% | 15.81M▲ 13.3% | 18.92M▲ 19.7% |
Asset Turnover | 0.90x | 1.69x | 0.42x | 0.43x |
Asset Growth % | - | 183.95% | 13.28% | 19.67% |
Total Current Liabilities | 2.38M | 1.41M | 993.06K | 1.73M |
Accounts Payable | 1.89M | 1.41M | 827.15K | 1.63M |
Days Payables Outstanding | 365.65 | 46.8 | 90.09 | 257.95 |
Short-Term Debt | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 490K | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 |
Current Ratio | 2.07x | 9.88x | 15.86x | 10.71x |
Quick Ratio | 2.07x | 9.63x | 15.86x | 10.71x |
Cash Conversion Cycle | - | -34.98 | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
Total Liabilities | 2.38M | 1.41M | 993.06K | 1.73M |
Total Debt | 0 | 0 | 0 | 0 |
Net Debt | -4.18M | -7.1M | -9.69M | -11.76M |
Debt / Equity | - | - | - | - |
Debt / EBITDA | - | - | - | - |
Net Debt / EBITDA | -1.65x | -0.70x | -4.91x | -4.58x |
Interest Coverage | - | 1274.61x | - | - |
Total Equity | 2.54M▲ 0% | 12.55M▲ 394.8% | 14.82M▲ 18.1% | 17.19M▲ 16.0% |
Equity Growth % | - | 394.79% | 18.11% | 16.01% |
Book Value per Share | 0.03 | 0.09 | 0.08 | 0.41 |
Total Shareholders' Equity | 2.54M | 12.55M | 14.82M | 17.19M |
Common Stock | 0 | 0 | 14.23K | 14.23K |
Retained Earnings | 2.54M | 12.55M | 14.8M | 17.17M |
Treasury Stock | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 |
NNNN Cash Flow Statement
Anbio Biotechnology Class A Ordinary Shares (NNNN) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
Cash from Operations | 4.18M | 4.45M | 898.37K | 2.08M |
Operating CF Margin % | 94.42% | 18.9% | 13.38% | 25.42% |
Operating CF Growth % | - | 6.4% | -79.81% | 131.57% |
Net Income | 2.54M | 10.01M | 2.25M | 2.37M |
Depreciation & Amortization | 0 | 6.25K | 12.06K | 0 |
Stock-Based Compensation | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | -40.87K | -163.39K | -337.1K |
Working Capital Changes | 1.65M | -5.53M | -1.2M | 44.65K |
Change in Receivables | -717.5K | 717.5K | -1.88M | 820.17K |
Change in Inventory | 0 | -353.87K | 353.87K | 0 |
Change in Payables | 1.89M | -481.82K | -580.89K | 798.1K |
Cash from Investing | 0 | -1.53M | 1.73M | 337.1K |
Capital Expenditures | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | 0% | - | - |
Acquisitions | 0 | 0 | 0 | 0 |
Investments | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 |
Cash from Financing | 0 | 0 | -42.84K | -344.61K |
Debt Issued (Net) | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -42.84K | -344.61K |
Net Change in Cash | 4.18M▲ 0% | 2.92M▼ 30.1% | 2.59M▼ 11.5% | 2.07M▼ 19.8% |
Free Cash Flow | 4.18M▲ 0% | 4.45M▲ 6.4% | 898.37K▼ 79.8% | 2.08M▲ 131.6% |
FCF Margin % | 94.42% | 18.9% | 13.38% | 25.42% |
FCF Growth % | - | 6.4% | -79.81% | 131.57% |
FCF per Share | 0.04 | 0.03 | 0.00 | 0.05 |
FCF Conversion (FCF/Net Income) | 1.65x | 0.44x | 0.40x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 |
NNNN Key Ratios
Anbio Biotechnology Class A Ordinary Shares (NNNN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Return on Equity (ROE) | 100% | 132.75% | 16.47% | 14.83% |
Return on Invested Capital (ROIC) | - | 402.54% | 27.81% | 28.34% |
Gross Margin | 57.4% | 53.36% | 50.07% | 71.9% |
Net Margin | 57.26% | 42.52% | 33.58% | 28.99% |
Interest Coverage | - | 1274.61x | - | - |
FCF Conversion | 1.65x | 0.44x | 0.40x | 0.88x |
Revenue Growth | - | 431.67% | -71.49% | 21.95% |
Related:NNNN Dividend History·NNNN Revenue History·NNNN Price History·NNNN P/E History·NNNN Financial Ratios·NNNN Institutional Holders
NNNN Frequently Asked Questions
Anbio Biotechnology Class A Ordinary Shares (NNNN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $16.1M in revenue for fiscal year 2024. This represents a 264% increase from $4.4M in 2021.
Anbio Biotechnology Class A Ordinary Shares (NNNN) grew revenue by 21.9% over the past year. This is strong growth.
Yes, Anbio Biotechnology Class A Ordinary Shares (NNNN) is profitable, generating $5.0M in net income for fiscal year 2024 (29.0% net margin).
Dividend & Returns
Anbio Biotechnology Class A Ordinary Shares (NNNN) has a return on equity (ROE) of 14.8%. This is reasonable for most industries.
Anbio Biotechnology Class A Ordinary Shares (NNNN) generated $3.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.